» Articles » PMID: 33680991

Role of Cytokines in Experimental and Human Visceral Leishmaniasis

Overview
Date 2021 Mar 8
PMID 33680991
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Visceral Leishmaniasis (VL) is the most fatal form of disease leishmaniasis. To date, there are no effective prophylactic measures and therapeutics available against VL. Recently, new immunotherapy-based approaches have been established for the management of VL. Cytokines, which are predominantly produced by helper T cells (Th) and macrophages, have received great attention that could be an effective immunotherapeutic approach for the treatment of human VL. Cytokines play a key role in forming the host immune response and in managing the formation of protective and non-protective immunities during infection. Furthermore, immune response mediated through different cytokines varies from different host or animal models. Various cytokines viz. IFN-γ, IL-2, IL-12, and TNF-α play an important role during protection, while some other cytokines viz. IL-10, IL-6, IL-17, TGF-β, and others are associated with disease progression. Therefore, comprehensive knowledge of cytokine response and their interaction with various immune cells is very crucial to determine appropriate immunotherapies for VL. Here, we have discussed the role of cytokines involved in VL disease progression or host protection in different animal models and humans that will determine the clinical outcome of VL and open the path for the development of rapid and accurate diagnostic tools as well as therapeutic interventions against VL.

Citing Articles

Expression of key cytokines in dog macrophages infected by Leishmania tarentolae opening new avenues for the protection against Leishmania infantum.

Louzada-Flores V, Latrofa M, Mendoza-Roldan J, Lucente M, Epis S, Varotto-Boccazzi I Sci Rep. 2024; 14(1):27565.

PMID: 39528528 PMC: 11554803. DOI: 10.1038/s41598-024-78451-x.


The Parasitemia has Contributed to the Severity of Cases of Visceral Leishmaniasis.

Campelo C, Medvedovsky A, de Holanda P, de Oliveira D, de Albuquerque-Pinto L, Melo L Indian J Microbiol. 2024; 64(2):511-519.

PMID: 39011003 PMC: 11246353. DOI: 10.1007/s12088-023-01182-6.


Unmasking the Mechanism behind Miltefosine: Revealing the Disruption of Intracellular Ca Homeostasis as a Rational Therapeutic Target in Leishmaniasis and Chagas Disease.

Benaim G, Paniz-Mondolfi A Biomolecules. 2024; 14(4).

PMID: 38672424 PMC: 11047903. DOI: 10.3390/biom14040406.


Transcriptional signatures in human macrophage-like cells infected by Leishmania infantum, Leishmania major and Leishmania tropica.

Diotallevi A, Bruno F, Castelli G, Persico G, Buffi G, Ceccarelli M PLoS Negl Trop Dis. 2024; 18(4):e0012085.

PMID: 38578804 PMC: 11023634. DOI: 10.1371/journal.pntd.0012085.


CD4 Th1 and Th17 responses and multifunctional CD8 T lymphocytes associated with cure or disease worsening in human visceral leishmaniasis.

de Franca M, Rodrigues L, Barreto A, da Cruz G, Aragao-Santos J, da Silva A Front Immunol. 2024; 15:1277557.

PMID: 38410517 PMC: 10895669. DOI: 10.3389/fimmu.2024.1277557.


References
1.
Dayakar A, Chandrasekaran S, Kuchipudi S, Kalangi S . Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy. Front Immunol. 2019; 10:670. PMC: 6459942. DOI: 10.3389/fimmu.2019.00670. View

2.
Hart P, Whitty G, Piccoli D, Hamilton J . Control by IFN-gamma and PGE2 of TNF alpha and IL-1 production by human monocytes. Immunology. 1989; 66(3):376-83. PMC: 1385223. View

3.
Panaro M, Acquafredda A, Lisi S, Lofrumento D, Mitolo V, Sisto M . Nitric oxide production by macrophages of dogs vaccinated with killed Leishmania infantum promastigotes. Comp Immunol Microbiol Infect Dis. 2001; 24(3):187-95. DOI: 10.1016/s0147-9571(00)00026-6. View

4.
Porrozzi R, Pereira M, Teva A, Volpini A, Pinto M, Marchevsky R . Leishmania infantum-induced primary and challenge infections in rhesus monkeys (Macaca mulatta): a primate model for visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2006; 100(10):926-37. DOI: 10.1016/j.trstmh.2005.11.005. View

5.
Buxbaum L, Scott P . Interleukin 10- and Fcgamma receptor-deficient mice resolve Leishmania mexicana lesions. Infect Immun. 2005; 73(4):2101-8. PMC: 1087424. DOI: 10.1128/IAI.73.4.2101-2108.2005. View